NCPC's subsidiary has received the approval notice for the marketing application of Sulfate Polymyxin B chemical raw materials
I'm LongbridgeAI, I can summarize articles.
NCPC's subsidiary Huasheng Company recently received the notice of approval for the marketing application of Sulfate Polymyxin B chemical raw materials from the National Medical Products Administration. This drug is used to treat acute infections caused by sensitive strains of Pseudomonas aeruginosa, particularly suitable for urinary tract, meningitis, and bloodstream infections. It can be used for the treatment of severe infections when other drugs with lower potential toxicity are ineffective or contraindicated
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments